These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
195 related articles for article (PubMed ID: 12163627)
21. Early restaging positron emission tomography with 18F-fluorodeoxyglucose in aggressive non-Hodgkin's lymphomas: is it too easy to be true? Balzarotti M; Magagnoli M; Santoro A Ann Oncol; 2003 Jul; 14(7):1155-6. PubMed ID: 12853364 [No Abstract] [Full Text] [Related]
22. Prognostic value of PET using 18F-FDG in Hodgkin's disease for posttreatment evaluation. Guay C; Lépine M; Verreault J; Bénard F J Nucl Med; 2003 Aug; 44(8):1225-31. PubMed ID: 12902411 [TBL] [Abstract][Full Text] [Related]
23. 18F-FDG PET as a routine test for posttherapy assessment of Hodgkin's disease and aggressive non-Hodgkin's lymphoma: where is the evidence? Juweid ME J Nucl Med; 2008 Jan; 49(1):9-12. PubMed ID: 18077522 [No Abstract] [Full Text] [Related]
24. [Current status of nuclear medicine. Clinical application of FDG-PET for cancer diagnosis. Malignant lymphoma]. Higuchi T Nihon Igaku Hoshasen Gakkai Zasshi; 2002 May; 62(6):278-83. PubMed ID: 12073634 [TBL] [Abstract][Full Text] [Related]
26. [Positron-emission tomography with fluorine-18-deoxyglucose in the staging and control of patients with lymphoma. Comparison with clinico-radiologic assessment]. Mainolfi C; Maurea S; Varrella P; Alaia C; Imparato C; Alfano B; Abate G; Bazzicalupo L Radiol Med; 1998; 95(1-2):98-104. PubMed ID: 9636735 [TBL] [Abstract][Full Text] [Related]
27. Change of initial staging at early remission evaluation with FDG-PET/CT in Hodgkin lymphoma: a report of two cases. Molin D; Hagberg H; Suurküla M; Aström G Acta Oncol; 2010 May; 49(4):526-8. PubMed ID: 20397779 [No Abstract] [Full Text] [Related]
28. Positron emission tomography with [(18)F]FDG for therapy response monitoring in lymphoma patients. Spaepen K; Stroobants S; Verhoef G; Mortelmans L Eur J Nucl Med Mol Imaging; 2003 Jun; 30 Suppl 1():S97-105. PubMed ID: 12709831 [TBL] [Abstract][Full Text] [Related]
29. Positron emission tomography in non-Hodgkin's lymphoma: assessment of chemotherapy with fluorodeoxyglucose. Römer W; Hanauske AR; Ziegler S; Thödtmann R; Weber W; Fuchs C; Enne W; Herz M; Nerl C; Garbrecht M; Schwaiger M Blood; 1998 Jun; 91(12):4464-71. PubMed ID: 9616140 [TBL] [Abstract][Full Text] [Related]
30. Comparison of 18F-fluoro-2-deoxyglucose positron emission tomography and gallium-67 citrate scintigraphy for detecting malignant lymphoma. Shen YY; Kao A; Yen RF Oncol Rep; 2002; 9(2):321-5. PubMed ID: 11836600 [TBL] [Abstract][Full Text] [Related]
31. [Prognostic value of 18F-FDG positron emission tomography in the early evaluation of the efficiency of treatment in patients with non-Hodgkin lymphomas]. Khodzhibekova MM; Tiutin LA; Kostenikov NA; Il'in NV; Vinogradova IuN Vestn Rentgenol Radiol; 2014; (4):38-41. PubMed ID: 25775886 [TBL] [Abstract][Full Text] [Related]
32. Persistent tumor 18F-FDG uptake after a few cycles of polychemotherapy is predictive of treatment failure in non-Hodgkin's lymphoma. Jerusalem G; Beguin Y; Fassotte MF; Najjar F; Paulus P; Rigo P; Fillet G Haematologica; 2000 Jun; 85(6):613-8. PubMed ID: 10870118 [TBL] [Abstract][Full Text] [Related]
33. Fluorine-18 fluorodeoxyglucose positron emission tomography for lymphoma: incorporating new technology into clinical care. Kaplan LD Am J Med; 2002 Mar; 112(4):320-1. PubMed ID: 11893374 [No Abstract] [Full Text] [Related]
34. [(18)F]FDG in childhood lymphoma: clinical utility and impact on management. Montravers F; McNamara D; Landman-Parker J; Grahek D; Kerrou K; Younsi N; Wioland M; Leverger G; Talbot JN Eur J Nucl Med Mol Imaging; 2002 Sep; 29(9):1155-65. PubMed ID: 12192560 [TBL] [Abstract][Full Text] [Related]
35. [FDG-PET on the day after first chemotherapy in malignant lymphoma]. Yamane T; Daimaru O; Itoh S; Nagata T; Yoshiya K; Itoh S; Uchida H; Shinai T; Imai T; Ohishi H Nihon Igaku Hoshasen Gakkai Zasshi; 2002 Dec; 62(14):839-42. PubMed ID: 12607955 [TBL] [Abstract][Full Text] [Related]
36. Non-Hodgkin lymphoma and Hodgkin disease: coregistered FDG PET and CT at staging and restaging--do we need contrast-enhanced CT? Schaefer NG; Hany TF; Taverna C; Seifert B; Stumpe KD; von Schulthess GK; Goerres GW Radiology; 2004 Sep; 232(3):823-9. PubMed ID: 15273335 [TBL] [Abstract][Full Text] [Related]
37. Prognostic significance of positron emission tomography using fluorine-18-fluorodeoxyglucose in patients treated for malignant lymphoma. Cremerius U; Fabry U; Neuerburg J; Zimny M; Bares R; Osieka R; Büll U Nuklearmedizin; 2001 Feb; 40(1):23-30. PubMed ID: 11373935 [TBL] [Abstract][Full Text] [Related]
38. The role of PET in Hodgkin's lymphoma and its impact on radiation oncology. Kobe C; Dietlein M; Kriz J; Furth C; Fuchs M; Borchmann P; Engert A; Eich HT Expert Rev Anticancer Ther; 2010 Sep; 10(9):1419-28. PubMed ID: 20836677 [TBL] [Abstract][Full Text] [Related]
39. The value of Ga-67 scintigraphy and F-18 fluorodeoxyglucose positron emission tomography in staging and monitoring the response of lymphoma to treatment. Bar-Shalom R; Mor M; Yefremov N; Goldsmith SJ Semin Nucl Med; 2001 Jul; 31(3):177-90. PubMed ID: 11430525 [TBL] [Abstract][Full Text] [Related]
40. The impact of FDG positron emission tomography imaging on the management of lymphomas. Shah N; Hoskin P; McMillan A; Gibson P; Lowe J; wong WL Br J Radiol; 2000 May; 73(869):482-7. PubMed ID: 10884743 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]